Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease

Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease

Background: Anakinra, canakinumab and tocilizumab are all effective alternative treatment choice in patients with Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) adult onset Still’s disease (AOSD) compared to canakinumab and tocilizumab. Objective: Aim of this study w...

Full description

Bibliographic Details
Main Authors: Roberto Ravasio, Roberto Giacomelli, Stefano Bianchi
Format: Article
Language:English
Published: AboutScience Srl 2020-09-01
Series:Global & Regional Health Technology Assessment
Subjects:
Adult onset Still’s disease
Anakinra
Budget impact
Italian National Health Service
Still’s disease
Systemic juvenile idiopathic arthritis
Online Access:https://journals.aboutscience.eu/index.php/grhta/article/view/2140

Internet

https://journals.aboutscience.eu/index.php/grhta/article/view/2140

Similar Items